[1] 陈伟伟,高润霖,刘力生,等.中国心血管报告2017概要[J].中国循环杂志,2018,33(1):1-8. [2] 高血压合理用药指南(第2版)[J].中国医学前沿杂志(电子版),2017,9(7):28-126. [3] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56 [4] Suvarna B S.Role of pharmacogenomics in the drug development.[J]. Kathmandu University medical journal (KUMJ), 2009, 7(26) : 172-6. [5] 孙晓燕,周丽娟,吕朋举,等.河南汉族人群抗高血压药物相关基因多态性与高血压发病及降压效果的关联研究[J/OL].中国医院药学杂志:1-8. [6] 林芬,吴泳浩,许嘉欣,等.潮州地区原发性高血压患者抗高血压药物相关基因多态性分析[J].检验医学与临床,2020,17(23):3420-3424. [7] 任凌雁,靳倩,廖喆,等.贵州原发性高血压人群相关药物基因多态性研究[J].重庆医学,2019,48(23):4017-4019,4023. [8] 杨梅,肖智林,陈晓彬,等.抗高血压药物相关基因多态性在长沙县区高血压病人群中的分布[J].临床心血管病杂志,2019,35(6):559-563. [9] 皇甫卫忠. AT1R、ACE、CYP11B2、ECE-1、CYP2C9、MDR1基因多态性对蒙、汉族人群高血压易感性以及厄贝沙坦和贝那普利降压效果的影响[D].南方医科大学,2020. [10] 张荣秀. 新疆哈萨克族、维吾尔族高血压患者细胞色素P450 3A5基因多态性与氨氯地平预期降压疗效的关系[D].新疆医科大学,2018. [11] 钟志雄. 贵州布依族、汉族原发性高血压与AT_1R基因A1166C多态性及环境因素的相关性研究[D].贵州医科大学,2016. [12] Anne,Kristine,Anstensrud,et al. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study[J]. European Journal of Clinical Pharmacology, 2020, 76(5) : 673-683. [13] García-Martín Elenaet al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.[J]. Molecular diagnosis & therapy, 2006, 10(1) : 29-40. [14] Imaizumi Takahiroet al. Association of interactions between dietary salt consumption and hypertension-susceptibility genetic polymorphisms with blood pressure among Japanese male workers.[J]. Clinical and experimental nephrology, 2017, 21(3) : 457-464. [15] 马丽秋,王闰,于涛,等.抗高血压药物基因多态性研究进展[J].中国现代医生,2021,59(22):188-192. [16] Gong Hongtaoet al. Association of polymorphisms of CYP11B2 gene -344C/T and ACE gene I/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension.[J]. Journal of genetics, 2019, 98 [17] PaldenWangyel,GyemTshering,Kesara Na. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South‐East and East Asian populations: A systematic review[J]. Journal of Clinical Pharmacy and Therapeutics, 2019, 44(4): 508-524. [18] Yong-Fang Huet al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population[J]. ClinicaChimica Acta, 2005, 353(1) : 187-192. [19] 文娟,黄志军,袁洪,等.肾移植后高血压人群中CYP3A4*1G、CYP3A5*3和MDR1 C3435T基因多态性对氨氯地平降压疗效的影响[J].中国动脉硬化杂志,2011,19(1):55-60. [20] Amy I.Lynch et al. Pharmacogenetic Association of the NPPA T2238C Genetic Variant With Cardiovascular Disease Outcomes in Patients With Hypertension[J]. JAMA, 2008, 299(3): 296-307. |